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Abstract 
Multiple recent pharmacological clinical trials in neuropathic pain have failed to show beneficial 
effect of drugs with previously demonstrated efficacy, and estimates of drug efficacy seems to 
have decreased with accumulation of newer trials. However, this has not been systematically 
assessed. Here we analyze time-dependent changes in estimated treatment effect size in 
pharmacological trials together with factors that may contribute to decreases in estimated effect 
size. This study is a secondary analysis of data from a previous published NeuPSIG systematic 
review and meta-analysis, updated to include studies published up till March 2017. We included 
double-blind, randomized, placebo-controlled trials examining the effect of drugs for which we 
had made strong or weak recommendations for use in neuropathic pain in the previously 
published review. As the primary outcome, we used an aggregated number needed to treat (NNT) 
for 50% pain reduction (alternatively 30% pain reduction or moderate pain relief). Analyses 
involved 128 trials. NNT values increased from around 2-4 in trials published between 1982 and 
1999 to much higher (less effective) values in studies published from 2010 onwards. Several 
factors that changed over time, such as larger study size, longer study duration, and more studies 
reporting 50% or 30% pain reduction correlated with the decrease in estimated drug effect sizes. 
This suggests that issues related to the design, outcomes and reporting have contributed to 
changes in the estimation of treatment effects. These factors are important to consider in design 
and interpretation of individual study data and in systematic reviews and meta-analyses. 
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1. Introduction 
Neuropathic pain is pain caused by a lesion or disease affecting the somatosensory nervous 
system, and affects 6-8% of the general adult population [15;31]. Neuropathic pain is associated 
with a negative impact on quality of life and a relatively modest efficacy response to existing drugs 
[28;29]. In a recent systematic review and meta-analysis, which provided the basis for the latest 
recommendations on neuropathic pain pharmacotherapy [6], we demonstrated quite unfavorable 
effect sizes, with higher numbers needed to treat (NNT) for most neuropathic pain medications 
than with the NNT in previous systematic reviews [5;7]. NNT values for the most effective 
therapies tend to be in the region of 5-7 for drugs such as duloxetine, gabapentin, and pregabalin, 
for which most data are available. This means that only a minority of people with moderate or 
severe neuropathic pain achieve a clinically meaningful pain outcome. 
This apparent decrease in estimates of clinical drug efficacy is of concern, considering multiple 
recent negative clinical trials in neuropathic pain with drugs that either showed potential in 
preclinical studies or where previous positive trials existed [1;26]. Similar concerns have been 
raised in the literature on major depressive disorders and schizophrenia, where the results of 
randomized controlled trials (RCTs) are highly variable and many trials fail to show an effect of 
drugs that have previously proven effective [13;16;17]. There may be several explanations for this 
apparent decrease in drug effect size in trials over time, such as more stringent study design and 
larger studies, increased magnitude of the placebo response, or publication or time-lag bias 
[3;12;24]. Systematical analysis of this issue is therefore necessary. We need to understand how to 
better design future trials. The treatment Committee of the Special Interest Group on Neuropathic 
Pain (NeuPSIG) of the International Association for the Study of Pain therefore performed an 
exploratory analysis of neuropathic pain trials comparing first-, second-, and third-line treatment 
options to placebo [6] in order to analyze changes in NNT and to identify potential factors that 
could contribute to this apparent increase in NNT. The results of this analysis should help 
understand how to better design future trials in neuropathic pain. 
 
2. Material and methods 
This is a secondary exploratory analysis of a published systematic review and meta-analysis of 
studies published between 1982 and 2014 [6] supplemented with studies published after 2014. In 
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the published systematic review, we included double-blind, randomized, placebo-controlled trials 
(RCTs) lasting at least 3 weeks with at least 10 patients per group, that examined the effect of 
drugs for use in neuropathic pain and reported results up to January 2014 [6]. Included RCTs were 
identified via searches of the PubMed and EMBASE databases, the Cochrane Central Register of 
Controlled Trials, and via the WHO Registry Network and registries approved by the International 
Committee of Medical Journal Editors (ICMJE) [6]. Based on the Grading of Recommendations 
Assessment, Development, and Evaluation (GRADE), we assigned weak or strong 
recommendations for or against a drug or drug class’s use. For this study, we performed an 
additional free text search of recommended drugs in PubMed and clinicaltrials.gov including 
studies up to March 2017 (Fig. 1).  
 
2.1. Outcomes 
Our primary outcome of interest was NNT. NNT was calculated as the inverse of the risk difference 
with the fixed-effects Mantel-Haenszel method [10;11;21]. We also undertook cumulative analysis 
of NNT, in which the final value corresponds to random effects (DerSimonian-Laird) analysis. The 
number of responders was based on the number of patients with ≥50% pain intensity reduction if 
reported, otherwise ≥30% pain reduction, or alternatively at least moderate (or similar) pain relief. 
Other data extracted were: (1) trial outcome (positive or negative study, based on the effect on 
the primary outcome measure); (2) year of publication (for illustration categorized in periods 
1982-1999, 2000-2004, 2005-2009, 2010-2013, and 2014-2017); (3) study design (parallel or 
crossover); (4) study size (number of patients randomized to active drug treatment); (5) treatment 
duration in weeks (duration of each treatment arm in crossover trials); (6) study quality (The 
Oxford Quality Scale, also known as Jadad scale, which scores whether randomization and blinding 
is described appropriately and if there is a description of dropouts and withdrawals (scores ranged 
from 2-5, with higher scores denoting higher quality [14]); (7) number needed to harm (NNH) for 
number of patients who needed to be treated for one patient to drop out of the trial because of 
adverse events; (8) whether the estimation of the primary outcome was stated to be based on 
intention-to-treat (ITT) analysis or not; (9) whether any concomitant treatment other than rescue 
medication was allowed; (10) whether inert or active placebo was used; (11) Patient Global 
Impression of Change (PGIC) and (12) pain condition(s) under treatment. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 6 
2.2. Statistical analysis 
In order to test if there was a change in effect size of drugs in clinical trials in neuropathic pain 
from 1982 to 2017, we calculated the correlation between the effect size and publication year 
using Spearman’s correlation coefficient. To assess the correlation between effect size and 
publication year and the above mentioned variables, we also calculated the pairwise correlation 
between two variables using Spearman’s correlation coefficients. Positive correlations between 
the effect size and publication year and any of the above variables would indicate that these 
variables may contribute at least partially to the change over time. In correlation analyses 
publication year for unpublished studies was arbitrarily set to one year after the results were 
posted (2007-2016), and we used the Risk Difference (RD, NNT=1/RD)) instead of NNT due to 
problems with infinite and negative values for NNT when RD is negative or zero. In order to take 
the uncertainty on the estimates of RD into account, we performed a linear regression analysis 
with RD as the dependent variable and publication year as independent variable where the studies 
were weighted by 1/se2 (se: standard error of the estimated RD). Due to collinearity between 
variables, we did not perform multiple regression analysis [30]. Statistical analysis was performed 
with SPSS version 20 (IBM SPSS Statistics 20). 
 
3. Results  
We included 118 studies with 128 comparisons of a drug against placebo. We added 20 additional 
trials published between 2014 and March 2017 to the 108 trials between 1982 and 2013 (Fig. 
1)(references in supplementary material). Of the 128 trials, 125 provided information on trial 
outcome, 91 trials were positive and 34 negative, and 105 and 112 trials provided dichotomous 
values for NNT and NNH, respectively (Fig. 1). Most studies included patients with painful diabetic 
polyneuropathy (n=44) or postherpetic neuralgia (n=28), 14 studies examined central neuropathic 
pain, 10 peripheral nerve injury, 8 mixed painful polyneuropathy, 7 painful HIV polyneuropathy, 
and 17 mixed or other neuropathic pain conditions. Pregabalin was studied in 33 trials, tricyclic 
antidepressants in 22, serotonin-noradrenalin reuptake inhibitors in 18, gabapentin in 13, strong 
opioids in 11, botulinum-toxin type A in 8, capsaicin 8% patch in 8, tramadol in 7, gabapentin 
extended release or enacarbil in 6, and lidocaine 5% patch in 2 trials (comparisons to placebo). The 
8 unpublished studies with 9 comparisons with placebo, included patients with painful diabetic 
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polyneuropathy (n=8) and postherpetic neuralgia (n=1) and with pregabalin in 4, and amitriptyline, 
desvenlafaxine, duloxetine, gabapentin, and oxycodone in 1 trial each. 
 
3.1. Change in trial outcome based on year of publication 
Combining all drugs and all pain conditions, NNT increased over time from 1982 to 2017 
(Supplementary fig. 1) from around 1.6-3.0 to a final NNT of 7.2 (6.7-7.9) (Spearman’s Rho = 0.51, 
P < 0.001). Taking into account the standard error of the risk difference, there was also a 
statistically significant slope in the linear regression between publication year and the risk 
difference (inverse of NNT) (P = 0.0006). There was also a significant correlation between the year 
of publication and NNT when only those studies that were positive on the primary outcome were 
analyzed (Spearman’s Rho = 0.52, P <0.001). The combined NNT per year increased gradually with 
a step between 1991 and 1997 and in the mid-2000s and then stabilized after around 2008-2010 
(Fig. 2, Supplementary fig. 1).  
 
3.2. Factors associated with NNT values and publication year 
Correlation analysis showed that larger study size, longer study duration, and higher placebo 
responses were related to both more recent publication and higher NNT (lower RD) (Figs. 3 and 4, 
Supplementary table 1a). Studies where outcomes were based on ITT analysis (which was 
reported to have been done in 93% of parallel and 28% of crossover design studies), 30% or 50% 
pain reduction (compared to pain relief or unknown scales), and/or which had higher Oxford 
quality scores were also published later and had higher NNT (Figs. 3 and 4, Supplementary table 
1a). Similarly, lower active drug responses and studies with parallel group design (compared to 
crossover studies) were published more recently and had higher NNT values (Supplementary table 
1a). Importantly, most of these factors were highly correlated, e.g. parallel-group design studies 
more often reported ITT analysis than crossover studies; larger studies had higher placebo 
responses, were of longer duration, and more often reported 30 or 50% pain reduction, etc. 
(Supplementary table 1a). 
NNT values based on 50% pain reduction did not differ significantly from NNT values based on 
30% pain reduction (Spearman’s Rho = -0.02, P = 0.89). The use of an inert or active placebo did 
not change over time, and there was no significant difference in NNT values in studies using an 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 8 
inert or active placebo (Supplementary table 1a). Similarly, there was no difference in NNT values 
over time between studies allowing and not allowing concomitant treatment with other analgesics 
(Supplementary table 1a, Supplementary fig. 2). NNHs increased over time, but there was no 
significant change in the percentage who dropped out during active or placebo treatment due to 
side effects (Supplementary table 1a). In newer studies published from 2008 and beyond (n=71), 
the NNT correlated to study size, duration, and quality, and placebo response. 
We conducted additional analysis in parallel design studies (Supplementary table 1b). All the 
factors mentioned above were related to higher NNT except studies where outcomes were based 
on ITT analysis and 30% or 50% pain reduction as outcome measures, which were all more recent 
(Supplementary table 1b). In studies where NNT based on both 30% or 50% pain reduction and 
PGIC could be calculated, there was a tendency that NNT was lower when based on PGIC 
(Supplementary table 2).  
 
3.3. Drug classes and pain conditions 
Figure 5 illustrates the change in NNT over time for each drug class. While not part of our planned 
analysis, we observed that NNT values were affected by the maximum dose administered in a trial.  
When only pregabalin studies with maximum daily doses up 600 mg were included, NNT were 
lower (Supplementary fig. 3). Several recent trials assessing pregabalin as a positive control only 
used a maximum daily dose of 300 mg compared to many earlier trials using 600 mg. Drug dose 
may be important for other drug and drug classes also, but too few trials provided this information 
for other drugs than pregabalin. Tricyclic antidepressants were studied mainly in early trials 
(Supplementary fig. 4A) and the number of patients responding to active drug and placebo for 
each drug class are illustrated in Supplementary figure 4B. Cumulative NNT for tricyclic 
antidepressants, serotonin-noradrenaline reuptake inhibitors and pregabalin in daily doses up to 
600 mg are illustrated in Supplementary figure 5. There was no clear change in pain conditions 
examined over time, and NNT were similar across pain conditions, except for a tendency for high 
NNT in studies of painful polyneuropathy due to HIV, which also had high placebo responses 
(Supplementary fig. 6). Supplementary fig. 7 illustrates the NNT for each drug class for each of the 
pain conditions. The majority of trials that form the basis for treatment recommendations are 
performed in peripheral neuropathic pain. 
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3.4. Placebo responses 
The weak correlation between placebo response and publication year was mainly caused by low 
placebo responses in very early trials. For example, as can be seen from figure 3c, studies 
published before 1996 all had low placebo responses, and including only studies published after 
1995, there was no statistically significant increase in placebo responses in trials with increasing 
publication year (Spearman’s Rho = 0.10, P = 0.31). Similarly, there was no correlation between 
placebo response and publication year, if only studies that reported 30% or 50% pain reduction 
were included (Spearman’s Rho = 0.18, P = 0.13), nor, as discussed above, if only parallel group 
design studies were included. The correlation between placebo response and NNT did, however, 
persist after excluding studies before 1996 and studies that did not report 30 or 50% pain 
reduction (Spearman’s Rho > 0.40, P < 0.001). Large sample size and long study duration 
correlated with high placebo responses and parallel design studies had higher placebo responses 
than crossover studies (Supplementary table 1a). As can be seen from the L’Abbé plot in figure 6, 
studies that were negative on the primary outcome had both low and high placebo responses. 
While 83% of trials with a placebo response rate lower than 30% were positive on the primary 
outcome (i.e. showed superiority of the study drug over placebo), only 52% of trials with a placebo 
response rate above 30%, and 33% of trials with a placebo response above 33%, were positive on 
the primary outcome. 
 
4. Discussion  
The major finding from the present study was that estimated effect size of drug trials for 
neuropathic pain decreased from 1982 to 2017, with increases in overall NNT and NNT per drug 
class. This decrease was apparent until 2010 then the effect size tended to stabilize. Importantly, 
this change over time was paralleled by changes in study design. More specifically larger sample 
size, longer study duration, better reporting of randomization and blinding, ITT analysis and more 
complete reporting of efficacy (ie the use of 30 % or 50 % pain reduction as outcome measures) 
were all significantly associated with reduced effect size. In contrast, there was no difference in 
effect size whether NNT was based on 30% or 50% pain reduction, which is in line with studies in 
acute pain [23;25]. Similarly the use of concomitant medication did not affect effect size.  
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The increase in placebo response over time was explained mainly by low placebo responses in 
very early trials. It is possible that the placebo responses are less associated with trial failure than 
previously thought [8;19]. We did, however, find a reduced percentage of positive trial outcomes 
in studies with more than 30% placebo responders (although there are statistical explanations for 
such associations [27]). This is in line with studies of bipolar disorders [12] and depression [13;18], 
where a placebo response rate greater than 30% showed greatly reduced drug-placebo 
separation, supporting the suggestion that such trials might be considered failed or uninformative 
rather than negative trials.  
The changes in NNT and study design over time may be seen in light of the evolution in the 
standards for RCTs. Our understanding of biases has improved and along with changes in 
requirements from regulatory bodies, the standards for RCTs have changed. While early studies 
were typically small single-center crossover trials, a change in NNT appeared when large 
gabapentin trials were published, which pioneered a shift in trial design towards larger parallel 
group trials of longer duration and with multiple sites. In the mid-2000s, the FDA began to require 
a 12-week duration for phase 3 trials and clinical trials in the US migrated from academic medical 
centers to commercial centers in the community that conduct trials across many therapeutic 
areas, which may have influenced the second jump in NNT. The question is what is the “true NNT”. 
In early trials, the use of per-protocol-analysis and lack of reporting of 30% or 50% reduction in 
pain intensity may have overestimated the treatment effect (underestimated the NNT). In later 
trials, however, there may be an underestimation of the effect size. Although not analyzed in this 
study, it has been suggested that large multi-center trials may have a less careful patient selection 
and study implementation and integrity, which may underestimate treatment effects, because of 
the introduction of a higher rate of underlying variability [16;20]. Recruitment pressures at 
commercial sites and limited access to health care may also result in inflation of baseline scores 
and high placebo responses. Therefore, investigator and patient training and improved diagnostic 
accuracy and assessment, as well as implementation of methods to secure patient adherence have 
been advocated to improve trial assay sensitivity [16;22]. 
Several limitations of this study should be acknowledged. Although the study  included all high-
quality pharmacotherapy trials with 1st-3rd line agents in neuropathic pain, there were too few 
studies regarding each drug or each pain conditions to allow testing interactions, the role of 
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different drug doses or the role of fixed versus flexible dosing, and to allow examining each drug 
separately rather than lumping different drugs into drug classes. Because of the collinearity 
between factors, regression analyses were not feasible. Therefore, the presentation of the 
associations between factors is mainly descriptive and does not make it possible to identify 
whether variables independently explain the changes over time. A previous study using 
standardized effect size, which is the ratio of the treatment effect and the within-group standard 
deviation, did not find an association between publication year and standardized effect size [3], 
and it is possible that the decrease in estimated effect sizes with increasing publication year is 
partly related to the use of NNT as the primary outcome. There are limitations to the use of NNT 
as a summary measure of treatment effect, and other analyses using risk rations, standardized 
effect sizes or other measures may be relevant to consider in systematic reviews. Using other 
outcomes such as PGIC, pain relief, quality of life and pain impact, may, however, have yielded 
somewhat different results. Outcomes based on PGIC or pain relief may result in lower NNTs than 
outcomes based on reduction in pain intensity, and these types of sensitivity analyses should be 
encouraged in future trials.  We did not have access to single-patient data and may not have 
extracted all factors that could be associated with the study outcome, such as number of study 
sites, pain duration, compliance, comorbidities, age, and number of treatments tried before the 
trial, which may affect assay sensitivity [2-4]. Some of the factors included were not always clearly 
described in the papers. For example, ITT analysis may be mislabeled and is difficult to estimate in 
crossover trials [9], and too few studies used baseline observation carried forward methods to 
examine the impact of imputation method. Also, several possible important factors were rarely 
assessed or reported in the publications, such as patient expectation, pain characteristics and 
serum drug concentrations. We did not identify unpublished studies before 2007, and it is likely 
that several unpublished studies exist, although our primary analysis suggested minimal 
publication bias [6]. The correlation between year of publication and NNT persisted even if 
unpublished or negative trials were not included, suggesting that the increase in NNT over time 
was not only due to publication bias or delays in publication. Lastly, the drugs may have been 
included in trials for different purposes, e.g. establishing whether there was an effect of the drug 
over placebo in a given condition, to evaluate predictors for response, or to have an active control 
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for an investigational drug, and not all were designed to measure the magnitude of an overall 
treatment effect. 
 
5. Conclusion 
We examined the changes in effect sizes of neuropathic pain clinical trials in the past 35 years. 
Across all drug classes, the NNT has increased (estimated drug effect size decreased) over time, 
with stabilization around 2010. Altered study design methodology with larger study size and 
duration, as well as changes in reporting of outcomes paralleled this decrease in overall estimated 
drug effect sizes. Except for very low placebo responses in early trials, placebo responses did not 
increase over time, but high placebo responses were generally associated with higher NNTs. Our 
analysis supports the suggestions that systematic reviews and meta-analyses should go beyond 
the aggregate findings of a meta-analysis and carefully look at all characteristics of the individual 
studies. Developing alternative study designs and studying phenotype-specific drug effects may 
lead to improved drug development in the future. Thus to increase our understanding and to 
improve treatment, future studies should record detailed patient characteristics at baseline and 
meta-analysis should preferably be made on patient-level data. 
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Figure legends 
Figure 1. Flowchart of study selection. Number of studies indicate number of comparisons of a 
drug against placebo.  
aPlease see PRISMA flowchart in Finnerup, Attal et al. 2015 [6], bStudy outcome based on the 
primary outcome.  
Figure 2. Change in study outcome over time. 2a. Combined NNT (random effect) per year. 2b. 
Cumulative NNT (random effect). 105 studies provided dichotomous data for NNT calculation.  
Figure 3. Relation between publication year and a) study size (number of patients treated with 
active drug in individual studies), b) study duration, c) placebo response, and d) percentage of 
studies reporting intention-to-treat (ITT) analysis, 30 or 50% pain reduction for outcome NNT 
calculation, and with a high quality score (Oxford scale). Publication year for unpublished studies 
was arbitrarily set to one year after the results were posted. 
Figure 4. Relation between NNT in individual studies and a) study size (number of patients treated 
with active drug in individual studies), b) study duration, c) placebo response, and d) percentage of 
studies reporting intention-to-treat (ITT) analysis, 30 or 50% pain reduction for outcome NNT 
calculation, and with a high quality score (Oxford scale) 
Figure 5. Combined NNT values (fixed-effects Mantel-Haenszel method) for various drug classes in 
all central and peripheral neuropathic pain conditions for drug classes recommended for the 
treatment of neuropathic pain. The circle sizes indicate the relative number of patients who 
received active treatment drugs in studies for which dichotomous data were available. BTX-A: 
botulinum toxin type A; TCAs: tricyclic antidepressants; SNRIs: serotonin-noradrenaline reuptake 
inhibitors; Gabapentin ER: Gabapentin extended release or enacarbil. Publication year for 
unpublished studies was arbitrarily set to one year after the results were posted.  
Figure 6. L’Abbé plot of all studies. This plots the percentage of responders to active drug against 
the percentage of responders to placebo. Trials in which the active drug is better than the placebo 
(using a dichotomous outcome for NNT calculation) are in the upper left (above the line), while 
studies where placebo is better than the active drug are in the lower right (below the line). Studies 
that were positive on the primary outcome (showed superiority of the study drug over placebo) 
are indicated with blue circles and studies that were negative are indicated with red circles. The x-
axis shows percentage of patients in each study who responded to placebo with 50% pain 
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reduction (alternatively 30% pain reduction or moderate pain relief) and the y-axis shows the 
percentage who responded to active drug. Circle size indicates relative study size (number of 
patients treated with active drug). 
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Altered study design methodology have contributed to decreases in estimated drug effect size 
from randomized controlled trials in neuropathic pain in the past 35 years. 
Summary
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Supplementary table 1a. Correlation matrix. 
RD=Risk difference = 1/NNT (numbers needed to treat), RC_Harm = 1/NNH (numbers needed to harm). 
Supplementary Materials: figures, tables Click here to download Supplementary Materials: figures, tables
Supplementary_rev2.pdf
Supplementary table 1b. Correlation matrix. Parallel group design studies 
RD=Risk difference = 1/NNT (numbers needed to treat), RC_Harm = 1/NNH (numbers needed to harm). 
Supplementary table 2. NNT for 50% or 30% pain reduction and Patient Global Impression of Change (PGIC). 
NNT (50% or 30% pain 
reduction)
NNT (PGIC)
Pregabalin 7.0 (5.9-8.7) 5.4 (4.7-5.4) 
Capsaicin 8% patch 12.0 (8.3-21.4) 8.3 (6.3-12.2)
While not part of our planned analysis, the fact that studies where the NNT was based on 30% or 50% pain reduction had higher NNT 
compared to those that used pain relief encouraged further analysis. Pain relief scales were mainly used in early studies and very few 
studies reported both pain relief and 30% or 50% pain reduction, but for two drug classes several studies (pregabalin (n=17) and 
capsaicin 8% patches (n=7)) reported both 50% or 30% pain reduction and at least much (or alternatively at least some) improvement 
on the PGIC. Although PGIC is a combined outcome including also adverse effects, we compared NNT for pregabalin and capsaicin 8% 
trials and NNT was generally lower when based on PGIC (calculated based on the ITT population) than the NNT based on 50% or 30% 
pain reduction. 
Supplementary figure 1.
The relation between the risk difference (RD) (the inverse of NNT(numbers needed to treat) in individual studies and publication year. 
Line indicate a Loess fit line (50% of points of fit, Epanechnikov kernel).
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Supplementary figure 2.
No relation between numbers needed to treat (NNT) and numbers needed to harm (NNH) and percentage of studies with add-on treatment.
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Supplementary figure 3.
Combined NNT values (fixed-effects Mantel-Haenszel method) for various drug classes in all central and peripheral neuropathic pain conditions 
for drug classes recommended for the treatment of neuropathic pain. For pregabalin, only trials in doses up to 600 mg were included.
The circle sizes indicate the relative number of patients who received active treatment drugs in studies for which dichotomous data were available.
NNT: Numbers needed to treat. BTX-A: botulinum toxin type A; TCAs: tricyclic antidepressants; SNRIs: serotonin-noradrenaline reuptake inhibitors; 
Gabapentin ER: Gabapentin extended release or gabapentin enacarbil. 
Publication year for unpublished studies was arbitrarily set to one year after the results were posted. 
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Supplementary figure 4. Publication year for each study (A) and combined percentage responding to active drug and placebo (B) 
based on drug class.
TCA=Tricyclic antidepressants, SNRIs=serotonin-noradrenaline reuptake inhibitors, BTX-A: botulinum toxin type A, Gabapentin ER: Gabapentin
extended release or enacarbil
In figure A, each circle indicates one study (drug comparison to placebo). 
In figure B, the y-axis indicates the combined percentage of patients responding to active drug or placebo within each drug class.
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Supplementary figure 5. Cumulative NNT (random effect) of trials with tricyclic antidepressants (TCA), 
serotonin-noradrenaline reuptake inhibitors (SNRI), and pregabalin up to 600 mg daily. 
Supplementary figure 6. Publication year for each study (A), Combined NNT (B), and combined percentage responding to active drug 
and placebo (C) based on pain condition.
PHN=Postherpetic neuralgia, PPN=Painful polyneuropathy, DM=Diabetes mellitus, MX=Mixed, PNI=Peripheral nerve injury, CP=Central pain
In figure A, each circle indicates one study (drug comparison to placebo). 
In figure B, the y-axis indicates the combined NNT=Numbers needed to treat (fixed-effects Mantel-Haenszel method) within each pain condition. 
In figure C, the y-axis indicates the combined percentage of patients responding to active drug or placebo within each pain condition.
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Supplementary figure 7. Combined NNT values (fixed-effects Mantel-Haenszel method) for various drug classes in different pain conditions. The 
circle sizes indicate the relative number of patients who received active treatment drugs in studies for which dichotomous data were available. 
In B, only studies with pregabalin up to 600 mg per day are included.
NNT: Numbers needed to treat. BTX-A: botulinum toxin type A; TCAs: tricyclic antidepressants; SNRIs: serotonin-noradrenaline reuptake 
inhibitors; Gabapentin ER: Gabapentin extended release or gabapentin enacarbil. PHN=Postherpetic neuralgia, PPN=Painful polyneuropathy, 
DM=Diabetes mellitus, MX=Mixed, PNI=Peripheral nerve injury, CP=Central pain
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